Clincosm LogoSign in Get a demo

Retrospective Analysis to Describe Patient Profiles, Current Treatment Patterns and Economic Burden for Asthma Patients in UAE. A Descriptive Analysis of the Asthma Patient Population in the Emirate of Dubai With Respect to Healthcare Resource Utilization, Costs, and Asthma-related Treatment Pattern

Sponsor
AstraZeneca (Industry)
Overall Status
Recruiting
CT.gov ID
NCT03963141
Collaborator
(none)
120,000
Enrollment
1
Location
39.8
Anticipated Duration (Months)
3016.1
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This Retrospective cohort study with an overall objective of to perform a descriptive analysis of the asthma patient population in the Emirate of Dubai with respect to healthcare resource utilization, costs, and asthma-related treatment patterns and outcome.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    120000 participants
    Observational Model:
    Cohort
    Time Perspective:
    Retrospective
    Official Title:
    Retrospective Analysis to Describe Patient Profiles, Current Treatment Patterns and Economic Burden for Asthma Patients in UAE.
    Actual Study Start Date :
    Mar 7, 2019
    Anticipated Primary Completion Date :
    Jun 30, 2022
    Anticipated Study Completion Date :
    Jun 30, 2022

    Outcome Measures

    Primary Outcome Measures

    1. Asthma Patients Number [1 Year]

      Number of unique asthma patients in the database during December 2015 through November 2018(summarized annually).it will be computed in the follow-up period and will be reported as a percentage and number of visits per person per year (PPPY). Utilization will be considered "all-cause" if the associated medical claim(s) has a diagnosis code in any position for any condition.

    2. Asthma-related Cost [1 Year]

      Total asthma-related cost reported in the databse during December 2015 through November 2018(summarized annually).It will will be computed in the follow-up period and will be reported as a percentage and number of visits per person per year (PPPY). Utilization will be considered "asthma-related" if the associated medical claim(s) has ICD-10 diagnosis code for asthma as the principal diagnosis

    Secondary Outcome Measures

    1. Asthma-related hopitalizations cost [1 Year]

      Number of asthma related hopistalizations and cost reported in the database during December 2015 through Novemebr 2018(Summairzed annually)

    2. Astma-related prescription pattern [1 Year]

      Prescription pattern of asthma-related medication by drug class during December 2015 through November 2018

    3. Severity of Asthma per total number of patients [1 Year]

      Number of patients classified as Mild, moderate and severe asthmatic patinets as per the international guidlines.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • Minimum two claims with asthma diagnosis, 30 days apart, during the identification period

    • Minimum 12 months of baseline period

    • Age ≥ 18 years on the index date

    • Continuous enrolment during the baseline period and at least 180 days of follow-up period; enrolment will be defined based on at least one activity during each 90-day period from the index date

    Exclusion Criteria:

    • Diagnosis of COPD during the baseline period. Diagnosis of COPD will be defined as ≥1 medical claim with an ICD-10 diagnosis in any position

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Dha Claim Dubai United Arab Emirates

    Sponsors and Collaborators

    • AstraZeneca

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    AstraZeneca
    ClinicalTrials.gov Identifier:
    NCT03963141
    Other Study ID Numbers:
    • D2287R00139
    First Posted:
    May 24, 2019
    Last Update Posted:
    Jun 7, 2022
    Last Verified:
    Jun 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Asthma
    Financial Stress

    Study Results

    No Results Posted as of Jun 7, 2022